Drug Trial Radar · NCT04424511
Effects of Mass Drug Administration of Azithromycin on Mortality and Other Outcomes Among 1-11 Month Old Infants in Mali
Last checked: Nov 19, 2026Latest source record: May 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
149,201
Actual
Start
Oct 15, 2020
Primary completion
Dec 31, 2024
Study completion Dec 31, 2024
Sponsor
- Lead sponsor
- Tampere UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Center for Vaccine Development CVD-Mali, Bamako, Mali; University College London Hospitals; Tro Da Ltd, UK; Duke-NUS Graduate Medical School; Bill and Melinda Gates Foundation; Pfizer Inc. (Provider of study drugs)
- First posted
- Jun 11, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 29 days, up to 364 days
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The LAKANA trial will assess the impact on mortality and other health outcomes of quarterly and biannual azithromycin mass drug administration (MDA) when delivered to 1-11-month (29-364 days) old infants in a high-mortality setting where malaria is holoendemic but there is also a functioning seasonal malaria chemoprevention (SMC) program in place. The long-term goal is to more precisely define the role of mass azithromycin treatments as an intervention for reducing childhood mortality, and to determine the most effective treatment regimen. The main study hypotheses in terms of mortality effect are: i) Biannual azithromycin MDA to 1-11 month old infants reduces their mortality, ii) Quarterly azithromycin MDA to 1-11 month old infants reduces their mortality, iii) Quarterly azithromycin MDA has a bigger mortality effect than biannual MDA.
Conditions
- Mortality
Interventions
PlaceboDrug
Placebo mixture will be administered as a single dose in oral suspension form for children 1-11 months of age. Weight-based dosing will be used: single-dose of 0.5 ml / kg child weight.
AzithromycinDrug
Azithromycin will be administered as a single dose in oral suspension form for children 1-11 months of age. Weight-based dosing will be used: single-dose of 0.5 ml (20 mg) / kg child weight.
Primary outcomes
What the sponsor says the trial is designed to measure.
- MortalityTime frame: 3-month time interval (total of 8 intervals per cluster)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Center for Vaccine Development CVD-Mali
Bamako, Mali
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.